Abacavir Plus Lamivudine - Explore the Science & Experts | ideXlab

Scan Science and Technology

Contact Leading Edge Experts & Companies

Abacavir Plus Lamivudine

The Experts below are selected from a list of 54 Experts worldwide ranked by ideXlab platform

Miguel Angel Lopezruz – 1st expert on this subject based on the ideXlab platform

  • efficacy of pegylated interferon Plus ribavirin treatment in hiv hepatitis c virus co infected patients receiving Abacavir Plus Lamivudine or tenofovir Plus either Lamivudine or emtricitabine as nucleoside analogue backbone
    Journal of Antimicrobial Chemotherapy, 2008
    Co-Authors: Jose A Mira, Luis F Lopezcortes, Pablo Barreiro, Cristina Tural, M Torrestortosa, Patricia Martinrico, Maria J Riosvillegas, Jose Juan Hernandezburruezo, Dolores Merino, Miguel Angel Lopezruz

    Abstract:

    Objectives To compare the response to hepatitis C virus (HCV) therapy among human immunodeficiency virus (HIV)/HCV co-infected patients receiving a nucleos(t)ide reverse transcriptase inhibitor [N(t)RTI] backbone consisting of Abacavir Plus Lamivudine with that observed in subjects who receive tenofovir Plus Lamivudine or emtricitabine. Methods A total of 256 subjects, enrolled in a cohort of 948 HIV-infected patients who received pegylated interferon and ribavirin from October 2001 to January 2006, were included in this study. All patients were taking one protease inhibitor or one non-nucleoside reverse transcriptase inhibitor and Abacavir Plus Lamivudine or tenofovir Plus Lamivudine or emtricitabine as N(t)RTI backbone during HCV therapy. Sustained virological response (SVR) rates in both backbone groups were compared. Results In an intention-to-treat analysis, 20 out of 70 (29%) individuals under Abacavir and 83 out of 186 (45%) under tenofovir showed SVR (P = 0.02). N(t)RTI backbone containing tenofovir was an independent predictor of SVR in the multivariate analysis [adjusted odds ratio (95% CI), 2.6 (1.05-6.9); P = 0.03]. The association between Abacavir use and lower SVR was chiefly seen in patients with plasma HCV-RNA load higher than 600 000 IU/mL and genotype 1 or 4. Among patients treated with ribavirin dose /=13.2 mg/kg/day. Conclusions HIV-infected patients who receive Abacavir Plus Lamivudine respond worse to pegylated interferon Plus ribavirin than those who are given tenofovir Plus Lamivudine or emtricitabine as N(t)RTI backbone, especially in those receiving lower ribavirin doses.

C Henley – 2nd expert on this subject based on the ideXlab platform

  • efficacy and safety of Abacavir Plus Lamivudine versus didanosine Plus stavudine when combined with a protease inhibitor a nonnucleoside reverse transcriptase inhibitor or both in hiv 1 positive antiretroviral naive persons
    Hiv Clinical Trials, 2004
    Co-Authors: Rodger D Macarthur, Grace Peng, Li Chen, Richard M Novak, M Van Den Bergwolf, Michael J Kozal, L Besch, Teresa Yurik, Barry Schmetter, C Henley

    Abstract:

    Purpose: The combination of Abacavir + Lamivudine (ABC+3TC) versus didanosine + stavudine (ddI+d4T), each combined with other classes of antiretrovirals (ARVs) in ARV-naive patients, was compared for the combined endpoint of time to plasma HIV RNA >50 copies/mL (at or after the 8-month visit) or death (primary endpoint) in a nested substudy of an ongoing multicenter randomized trial. Method: The substudy enrolled 182 patients; mean HIV RNA and CD4+ cell counts at baseline were 5.1 log10 copies/mL and 212 cells/mm3, respectively. Results: After a median follow-up of 28 months, rates of primary endpoint were 57.2 and 67.8 per 100 person-years for the ABC+3TC and ddI+d4T groups (hazard ratio [HR] = 0.81, 95% confidence interval [CI] 0.58-1.14, p = .23). Conclusion: There was a trend for treatments containing ABC+3TC to be better than treatments containing ddI+d4T with respect to HIV RNA decreases, CD4+ cell count increases, and tolerability.

Jose A Mira – 3rd expert on this subject based on the ideXlab platform

  • efficacy of pegylated interferon Plus ribavirin treatment in hiv hepatitis c virus co infected patients receiving Abacavir Plus Lamivudine or tenofovir Plus either Lamivudine or emtricitabine as nucleoside analogue backbone
    Journal of Antimicrobial Chemotherapy, 2008
    Co-Authors: Jose A Mira, Luis F Lopezcortes, Pablo Barreiro, Cristina Tural, M Torrestortosa, Patricia Martinrico, Maria J Riosvillegas, Jose Juan Hernandezburruezo, Dolores Merino, Miguel Angel Lopezruz

    Abstract:

    Objectives To compare the response to hepatitis C virus (HCV) therapy among human immunodeficiency virus (HIV)/HCV co-infected patients receiving a nucleos(t)ide reverse transcriptase inhibitor [N(t)RTI] backbone consisting of Abacavir Plus Lamivudine with that observed in subjects who receive tenofovir Plus Lamivudine or emtricitabine. Methods A total of 256 subjects, enrolled in a cohort of 948 HIV-infected patients who received pegylated interferon and ribavirin from October 2001 to January 2006, were included in this study. All patients were taking one protease inhibitor or one non-nucleoside reverse transcriptase inhibitor and Abacavir Plus Lamivudine or tenofovir Plus Lamivudine or emtricitabine as N(t)RTI backbone during HCV therapy. Sustained virological response (SVR) rates in both backbone groups were compared. Results In an intention-to-treat analysis, 20 out of 70 (29%) individuals under Abacavir and 83 out of 186 (45%) under tenofovir showed SVR (P = 0.02). N(t)RTI backbone containing tenofovir was an independent predictor of SVR in the multivariate analysis [adjusted odds ratio (95% CI), 2.6 (1.05-6.9); P = 0.03]. The association between Abacavir use and lower SVR was chiefly seen in patients with plasma HCV-RNA load higher than 600 000 IU/mL and genotype 1 or 4. Among patients treated with ribavirin dose /=13.2 mg/kg/day. Conclusions HIV-infected patients who receive Abacavir Plus Lamivudine respond worse to pegylated interferon Plus ribavirin than those who are given tenofovir Plus Lamivudine or emtricitabine as N(t)RTI backbone, especially in those receiving lower ribavirin doses.

  • Efficacy of pegylated interferon Plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving Abacavir Plus Lamivudine or tenofovir Plus either Lamivudine or emtricitabine as nucleoside analogue backbone
    Journal of Antimicrobial Chemotherapy, 2008
    Co-Authors: Jose A Mira, Pablo Barreiro, Cristina Tural, Luis F. López-cortés, M. Torres-tortosa, Patricia Martín-rico, María J. Ríos-villegas, José Juan Hernández-burruezo, Dolores Merino

    Abstract:

    Objectives To compare the response to hepatitis C virus (HCV) therapy among human immunodeficiency virus (HIV)/HCV co-infected patients receiving a nucleos(t)ide reverse transcriptase inhibitor [N(t)RTI] backbone consisting of Abacavir Plus Lamivudine with that observed in subjects who receive tenofovir Plus Lamivudine or emtricitabine. Methods A total of 256 subjects, enrolled in a cohort of 948 HIV-infected patients who received pegylated interferon and ribavirin from October 2001 to January 2006, were included in this study. All patients were taking one protease inhibitor or one non-nucleoside reverse transcriptase inhibitor and Abacavir Plus Lamivudine or tenofovir Plus Lamivudine or emtricitabine as N(t)RTI backbone during HCV therapy. Sustained virological response (SVR) rates in both backbone groups were compared. Results In an intention-to-treat analysis, 20 out of 70 (29%) individuals under Abacavir and 83 out of 186 (45%) under tenofovir showed SVR (P = 0.02). N(t)RTI backbone containing tenofovir was an independent predictor of SVR in the multivariate analysis [adjusted odds ratio (95% CI), 2.6 (1.05-6.9); P = 0.03]. The association between Abacavir use and lower SVR was chiefly seen in patients with plasma HCV-RNA load higher than 600 000 IU/mL and genotype 1 or 4. Among patients treated with ribavirin dose /=13.2 mg/kg/day. Conclusions HIV-infected patients who receive Abacavir Plus Lamivudine respond worse to pegylated interferon Plus ribavirin than those who are given tenofovir Plus Lamivudine or emtricitabine as N(t)RTI backbone, especially in those receiving lower ribavirin doses.